Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
89 hedge funds and large institutions have $114M invested in Clearside Biomedical in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 18 reducing their positions, and 14 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 18
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
3% more funds holding
Funds holding: 86 → 89 (+3)
0.39% less ownership
Funds ownership: 4.25% → 3.86% (-0.39%)
35% less call options, than puts
Call options by funds: $455K | Put options by funds: $701K
48% less capital invested
Capital invested by funds: $218M → $114M (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.01M |
| 2 |
AIC
AWM Investment Company
New York
|
+$1.67M |
| 3 |
NC
Nexthera Capital
New York
|
+$1.43M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$1.38M |
| 5 |
Two Sigma Investments
New York
|
+$754K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$16.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$7.6M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.34M |
| 4 |
Millennium Management
New York
|
-$2.75M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$1.39M |
CLSD Hedge Fund Activity: Q3 2018 in Review
89 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q3 2018, worth a combined $114M — down 48% from $218M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CLSD positions and 14 closed out — a net gain of 3 holders — while 34 added to existing stakes and 18 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $2.01M. The largest seller was RA Capital Management, exiting entirely with an estimated $16.3M sold.
- 89 institutional investors held Clearside Biomedical (CLSD) as of Q3 2018, up from 86 in Q2 2018.
- Funds reported $114M of Clearside Biomedical stock for Q3 2018, down 48% quarter-over-quarter.
- 17 funds opened new Clearside Biomedical positions in Q3 2018 and 14 closed out, a net change of +3 holders.
- The largest Clearside Biomedical buyer in Q3 2018 was JP Morgan Chase, an estimated $2.01M added.
- The largest Clearside Biomedical seller in Q3 2018 was RA Capital Management, an estimated $16.3M sold.
Based on aggregated 13F filings for Q3 2018.